MedTrace Logo

Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

NCT01342939 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2013-01-15

No results posted yet for this study

Summary

The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.

Conditions

  • Maturity-onset Diabetes of the Young

Interventions

OTHER

Oral Glucose Tolerance Test (OGTT)

50g waterfree glucose dissolved in 300ml water consumed over 5 min.

OTHER

iso glycaemic intravenous (iv) glucose infusion (IIGI)

20% glucose

DIETARY_SUPPLEMENT

Meal test

Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)

OTHER

Sitagliptin

Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones

OTHER

Incretin effect on sulphonyl urea treatment

Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Signe H Østoft, MD, phd stud · Diabetes Research Division, University Hospital Gentofte, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342939 on ClinicalTrials.gov